News Headlines

  1. Genprex Selects Leading Clinical And Commercial Contract Development And Manufacturing Organization For Manufacturing Scale Up Of Diabetes Gene Therapy 8/18/2026

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy program.

  2. VectorBuilder And Lir Therapeutics Partner To Advance AAV Capsids Designed For Clinical Success 8/18/2026

    VectorBuilder, a global leader in gene delivery technologies, and Lir Therapeutics, a company pushing the boundaries of vector engineering with AI, today announced a strategic collaboration to develop adeno-associated virus (AAV) capsids designed not only for strong biological performance, but also for the manufacturability and scalability required to bring gene therapies into the clinic.

  3. Andelyn Biosciences to Implement Curator® Platform To Develop And Manufacture Gene Therapy AAV9-GM2 For Queen's University To Treat GM2 Gangliosidoses 8/18/2026

    Andelyn Biosciences, Inc., a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen's University to develop and manufacture AAV9-GM2, a gene therapy candidate for the treatment of GM2 gangliosidoses, such as Tay-Sachs and Sandhoff diseases.

  4. Vector Science And Therapeutics Corp. Signs Amended, 10-Year Manufacturing And Testing Agreement With LyoGenesis Holdings 8/17/2026

    Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") announced today that its subsidiary, Vector Science and Therapeutics Operating Corp. ("VST"), has entered into an Amended and Restated Exclusive License and Manufacturing Agreement (the "Agreement"), effective August 13, 2026, with LyoGenesis Holdings LLC ("LyoGenesis"), amending and restating the parties' prior agreement dated July 6, 2026.

  5. Henlius And Sandoz Enter Strategic Collaboration To Unlock Global Value Of Biosimilars Platform 8/17/2026

    On August 17, 2026, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into a strategic collaboration with Sandoz (SIX: SDZ; OTCQX: SDZNY), a global leader in generics and biosimilars, covering up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components developed by Henlius.

  6. Pilot Project Between BioCytics And LIDE Biotech 8/13/2026

    BioCytics, Inc., and LIDE Biotech are proud to announce the formation of a strategic alliance to develop advanced screening platforms and companion diagnostics for immune-based cancer cell therapies. 

  7. Saptalis Pharmaceuticals And Coformer AI Partner To Develop Next-Generation Drug Formulations For Neurology And Oncology 8/13/2026

    Saptalis Pharmaceuticals and Coformer AI today announced a strategic research partnership to develop next-generation pharmaceutical formulations that address some of the industry's most persistent challenges, including poor solubility, low bioavailability, and dose-limiting toxicity. 

  8. NurExone Announces Binding MOU With Made Scientific For U.S. GMP Manufacturing And Commercial Supply Partnership 8/13/2026

    NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative therapies, today announced that its wholly owned U.S. subsidiary, Exo-Top Inc. ("Exo-Top"), together with the Company, has signed a binding memorandum of understanding ("MOU") with Made Scientific, Inc. (“Made Scientific”) to establish an exclusive U.S. Good Manufacturing Practice (“GMP”) manufacturing and commercial exosome supply partnership to support NurExone’s clinical and commercial activities.

  9. Cycle Pharmaceuticals Selects Forma Life Sciences To Establish U.S. Commercial Supply For FDA-Approved CAVHANZA (nilotinib) Orally Disintegrating Tablets 8/12/2026

    Cycle Pharmaceuticals (“Cycle”), a global pharmaceutical company focused on rare diseases, and Forma Life Sciences, Inc. (“Forma”), a U.S. contract development and manufacturing organization, today announced a commercial manufacturing agreement for CAVHANZA (nilotinib) orally disintegrating tablets.

  10. Bio Usawa And BioVax Partner To Strengthen Kenya's Biologics Manufacturing Ecosystem 8/11/2026

    Bio Usawa Biotech Limited (Kenya), a subsidiary of Bio Usawa Inc. (USA), and Kenya BioVax Institute have entered into a strategic partnership to advance the development, local manufacturing, and commercialization of affordable biologic medicines for Kenya and across Africa.